Navigation Links
Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces,a Broad, Patient-Specific Antibody Response

ncers such as prostate cancer."

Evidence of patient-specific immune responses associated with non patient- specific GVAX immunotherapy products has also been reported in other cancers. In August 2004, the company reported on data published in the Journal of Experimental Medicine from a Phase 1 clinical trial of GVAX immunotherapy for pancreatic cancer that provided evidence that patient-specific immune responses can be generated following treatment with this non patient-specific product. The article described detailed analyses of the immune response to the immunotherapy in three out of 14 patients who were long-term survivors and who also demonstrated strong T cell responses to mesothelin, a tumor- associated protein found in the majority of pancreatic cancers and in the GVAX immunotherapy for pancreatic cancer cells. The specificity of the T cell response to mesothelin was shown to be unique to each responding patient providing further scientific proof-of-concept for the company's GVAX immunotherapy strategy.

GVAX immunotherapy for prostate cancer is comprised of two prostate cancer cell lines that have been modified to secrete GM-CSF (granulocyte-macrophage colony stimulating factor), an immune stimulatory hormone, and irradiated for safety. GVAX cancer immunotherapy for prostate cancer is being developed as a non patient-specific, "off-the-shelf" pharmaceutical product.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Cerege
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
2. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
3. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
4. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
5. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
6. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
7. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
8. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
9. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
10. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
11. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
Post Your Comments:
(Date:4/20/2015)... -- This report analyzes the worldwide markets for Breast Pumps ... Pumps, and Powered Breast Pumps. The report provides separate comprehensive ... Japan , Europe , ... and forecasts are provided for the period 2014 through 2020. ... Market data and analytics are derived from primary and secondary ...
(Date:4/20/2015)... 2015 Actavis plc (NYSE: ACT ... , Chief Communications Officer, will retire from Actavis ... conjunction with Mayr,s retirement, Alex Kelly , ... Chief Communications Officer, effective immediately. Prior to joining ... President, Chief Communications Officer, Public Affairs and Investor ...
(Date:4/20/2015)... , April 20, 2015 This report analyzes ... in US$ Million. The report provides separate comprehensive analytics ... Europe , and Rest of World. Annual ... through 2020. Also, a seven-year historic analysis is provided ... from primary and secondary research. Company profiles are primarily ...
Breaking Medicine Technology:World Breast Pumps Industry 2World Breast Pumps Industry 3World Breast Pumps Industry 4World Breast Pumps Industry 5World Breast Pumps Industry 6World Breast Pumps Industry 7World Breast Pumps Industry 8World Breast Pumps Industry 9World Breast Pumps Industry 10World Breast Pumps Industry 11World Breast Pumps Industry 12World Breast Pumps Industry 13World Breast Pumps Industry 14Actavis Announces Retirement of Charles M. Mayr 2Actavis Announces Retirement of Charles M. Mayr 3World Medical Equipment Rental and Leasing Industry 2World Medical Equipment Rental and Leasing Industry 3World Medical Equipment Rental and Leasing Industry 4World Medical Equipment Rental and Leasing Industry 5World Medical Equipment Rental and Leasing Industry 6World Medical Equipment Rental and Leasing Industry 7
... of Minnesota is opening a new helipad on its Minneapolis ... they need it most. The new helipad ... minutes, by eliminating the need to move patients from the ... a distance of about a half a mile. ...
... 2011 Abaxis, Inc. (NasdaqGS: ABAX), a medical products ... Kenneth Aron, Chief Technology Officer, will present at the ... Investor Forum on Thursday, November 10, 2011 at 1:20 ... Grand Hyatt New York Hotel in New York City. ...
Cached Medicine Technology:Children's Hospitals and Clinics of Minnesota Opens New Helipad on its Minneapolis Campus 2Abaxis, Inc. to Present at Sidoti & Company's New York II Emerging Growth Institutional Investor Forum 2
(Date:4/21/2015)... CA (PRWEB) April 21, 2015 The ... at the beautiful Governor’s Academy prep school in Byfield, ... July 10-12, 2015, for boys entering grades 6-12. , ... and supplement the players’ fall coaching. , ... athletes. Not only are these the most unsung positions ...
(Date:4/21/2015)... The Science Museum of Virginia welcomes theoretical ... its Lunch Break Science program. On Wednesday, April 29, Dr. ... guests from the subatomic world of quantum mechanics to astronomical ... members of the community to grab lunch and take a ... will delve into the nucleus and dissect the complex world ...
(Date:4/21/2015)... Hills, CA (PRWEB) April 21, 2015 Dr. ... has just released an interesting infographic that takes a close ... millennials. , The new infographic, which appears on both Dr. ... The Rise of Plastic Surgery in the Age of the ... surgery in Beverly Hills to a variety of A-list ...
(Date:4/21/2015)... (PRWEB) April 21, 2015 Renewable energy, ... a few of the Earth Day topics USM ... and national leaders debate the affect of climate change ... variety of subject matter touching on the environmental concerns ... segments will delve into sustainable lifestyles, clean air options, ...
(Date:4/21/2015)... Freeslate, Inc ., the leading provider ... that the Centre for Catalysis Research and Innovation ... a Freeslate Core Module 3 (CM3) Reaction Screening ... to accelerate current research programs. The systems will be ... be available to academic users and industrial collaborators/ partners ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and The Northeast Football Clinic Announce 2015 Lineman/Linebacker Clinic Schedule 2Health News:Quarks and Forks at the Science Museum of Virginia 2Health News:Beverly Hills Plastic Surgery Expert Dr. Zain Kadri Releases Thought-Provoking New Infographic 2Health News:USM Studios’ Programming Focuses on the Environment 2Health News:University of Ottawa Selects Freeslate Reaction Screening System to Support High-Throughput Research at the Centre for Catalysis Research and Innovation 2Health News:University of Ottawa Selects Freeslate Reaction Screening System to Support High-Throughput Research at the Centre for Catalysis Research and Innovation 3
... , , , ... (Nasdaq: HTWR ) (ASX: HIN) announced today the completion ... stock in a private placement in the United States and Australia ... a purchase price of US$22.00 per share resulting in gross proceeds ...
... pose dangers, experts say , MONDAY, Aug. 17 (HealthDay News) ... amounts of indoor ozone, then "spit" it out in the ... lungs, new research suggests. , "They are saying that compounds ... irritation to the skin," explained one expert, Rajat Sethi, an ...
... two disorders , MONDAY, Aug. 17 (HealthDay News) -- Dr. ... commonly used to combat high blood pressure can help prevent ... But people in the know tend to listen carefully to ... University, because one of his ideas was crucial in the ...
... BEDFORD, Mass., Aug. 17 Insulet Corporation (Nasdaq: ... its OmniPod(R) Insulin Management System, today announced the appointment of ... created role, Mr. Devlin will lead the Company,s Sales and ... , "Peter brings a distinguished track record ...
... interaction, researchers prevent disease production , MONDAY, Aug. ... to block HIV infections in the lab with synthetic ... , In the study, researchers developed synthetic molecules that ... called gp41 to interact with proteins in host cells. ...
... monitored in those with head and neck malignancies, researchers ... levels of post-treatment pain in head and neck cancer ... U.S. researchers have found. , Their study included 339 ... of life at diagnosis and three, six, nine and ...
Cached Medicine News:Health News:HeartWare International, Inc. Closes US$60 Million Financing 2Health News:HeartWare International, Inc. Closes US$60 Million Financing 3Health News:Toxins May Form When Skin, Indoor Ozone Meet 2Health News:Toxins May Form When Skin, Indoor Ozone Meet 3Health News:Blood Pressure Drug Might Work Against MS 2Health News:Blood Pressure Drug Might Work Against MS 3Health News:Insulet Appoints Peter J. Devlin as Chief Commercial Officer 2Health News:Synthetic Protein Thwarts HIV Infection in Lab 2Health News:Pain Level May Predict Survival in Certain Cancer Patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: